《中国糖尿病杂志》官方网站

20

您的位置:首页 > 中国糖尿病杂志 > 2013年 > 7期

噻唑烷二酮类药物对2型糖尿病患者骨代谢的影响及其机制

来自:中国糖尿病杂志  编辑:侯文芳 肖文华 洪天配|点击数:|2013-07-18

  ·文献综述·

  【摘要】 噻唑烷二酮(TZDs)类药物是近年来常用的一类口服降糖药,其可能会对糖尿病患者的骨代谢产生不良影响,使骨密度下降,甚至导致骨折风险增加。本

  文就TZDs类药物对糖尿病患者骨代谢的影响及其可能机制进行综述。

  【关键词】噻唑烷二酮类药物;2型糖尿病;骨代谢

The effects and mechanisms of thiazolidinediones on bone metaborism in the patients with type 2 diabetes Hou Wen-Fang, Xiao,Wen-Hua Hong Tian-Pei Department of Endocrinology, Peking University Third Hospital。Beijing 100191,China

  【Abstract】 Thiazolidinediones (TZDs) , selective agonists of peroxisome proliferator-activated receptor gamma , are kinds of oral anti-diabetic drugs. Several large-scale clinical trials have reported that TZDs may contribute to decreased bone mineral density and increased risk of fracture. In this article, we review the effects and mechanisms of thiazolidinediones on bone metabolism in the patients with type 2 diabetes.

  【Key words】 Thiazolidinediones; Diabetes mellitus,Type 2; Bone metabolism

上一篇:讲座 下一篇:双时相门冬胰岛素50治疗2型糖尿病的安全性和有效性